Evidence map›Paper›PMID 42836952›Full record

ArticleJournal of hematopathology2026

Early-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation.

Gökhan Burul, Çagla Karaoglan, Erdem Bektaş, Cemal Bes, Leylagül Kaynar, İstemi Serin, Şeniz Öngören

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gökhan BurulDepartment of Hematology, İstanbul Başakşehir Çam and Sakura City Hospital, G-434 Street No: 2L, Basaksehir, Istanbul, 34480, Turkey. gokhanburul@hotmail.com.ORCID https://orcid.org/0000-0003-3702-536X
Çagla KaraoglanDepartment of Pathology, İstanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Erdem BektaşDepartment of Rheumatology, İstanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Cemal BesDepartment of Rheumatology, İstanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Leylagül KaynarDepartment of Hematology, Medipol University, Istanbul, Turkey.
İstemi SerinDepartment of Hematology, İstanbul Başakşehir Çam and Sakura City Hospital, G-434 Street No: 2L, Basaksehir, Istanbul, 34480, Turkey.
Şeniz ÖngörenDepartment of Hematology, İstanbul Başakşehir Çam and Sakura City Hospital, G-434 Street No: 2L, Basaksehir, Istanbul, 34480, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVEXAS syndrome is a somatic autoinflammatory disorder caused by UBA1 mutations in hematopoietic progenitor cells, typically affecting older men and characterized by systemic inflammation and hematologic abnormalities. Early-onset cases are extremely rare. CASE PRESENTATION: We report a 25-year-old male patient presenting with recurrent fever, weight loss, arthralgia, and inflammation mimicking orbital cellulitis. Imaging demonstrated orbital soft tissue inflammation. Laboratory investigations revealed macrocytic anemia, leukopenia, thrombocytopenia, and elevated inflammatory markers; FDG-PET/CT showed splenomegaly and hypermetabolic lymphadenopathy. Bone marrow examination revealed hypercellularity, multilineage morphological abnormalities, and vacuolated blasts. Following exclusion of infectious and classical autoinflammatory diseases, the somatic UBA1 c.121A > G (p.Met41Val) mutation confirmed VEXAS syndrome. The patient initially responded to corticosteroids but subsequently developed refractory disease and progressive pancytopenia despite tocilizumab therapy. He underwent allogeneic hematopoietic stem cell transplantation from a 10/10 HLA-matched sibling donor using a myeloablative conditioning regimen. At 3 months post-transplantation, 99% donor chimerism and hematologic remission were achieved.

conclusionVEXAS syndrome should be considered in young adults presenting with unexplained systemic inflammation and cytopenias, even with atypical manifestations such as orbital cellulitis. Early genetic evaluation is crucial for diagnosis, and allogeneic stem cell transplantation may provide effective disease control in refractory cases.

Indexed as

Hematopoietic Stem Cell TransplantationOrbital CellulitisAdultDiagnosis, DifferentialHumansMaleMyelodysplastic SyndromesSkin Diseases, GeneticSyndromeTransplantation, HomologousTreatment OutcomeUbiquitin-Activating EnzymesUbiquitin-Activating EnzymesAllogeneic hematopoietic stem cell transplantationOcular inflammationOrbital cellulitisUBA1 mutationVEXAS syndrome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.